semaglutide wada Are GLP-1s Performance-Enhancing Drugs? Does Ozempic Affect Athletic Performance?

Novo Nordisk is ending its Phase III FLOW trial ahead of schedule after an interim analysis of the kidney outcomes study of semaglutide found a very high likelihood of study success

This global initiative reframed obesity as a chronic, systemic disease rather than a mere risk factor

Retatrutide may deliver greater weight loss than existing drugs by acting on three hormones, but risks like side effects, muscle loss, and emotional changes remain concerns.

Satisfy your cravings with delicious GLP-1 dessert recipes that support weight loss

There may also be an increase in strategic partnerships and acquisitions as companies look to bolster their portfolios with proven subq GLP-1 assets